Clinical Research Informer

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet

The Pharma Data

JANUARY 31, 2021

Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag© Technology. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. —- End —-.

Clinical Trials

Clinical Trials Clinical Trials Vaccination Vaccine

Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates

The Pharma Data

DECEMBER 3, 2020

Utilizing Clover’s proprietary Trimer-Tag © technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag © Technology. Trimer-Tag © is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins.

Vaccination

Vaccination Vaccine Immune Response Protein

J&J gets first approval for multiple myeloma bispecific Tecvayli

pharmaphorum

AUGUST 25, 2022

It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK’s first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin), Bristol-Myers Squibb/bluebird bio’s CAR-T therapy Abecma (idecabtagene vicleucel) and J&J/Legend Biotech’s CAR-T Carvykti (ciltacabtagene autoleucel).

Antibody

Antibody Marketing Drugs Medicine

Axsome bounces back as FDA clears depression drug

pharmaphorum

AUGUST 21, 2022

NMDA antagonist dextromethorphan is an ingredient found in cough syrups, while bupropion is an established antidepressant that was originally developed by GSK and sold as Wellbutrin. In this product, bupropion is designed to increase levels of dextromethorphan in the blood and extend its half-life.

Drugs

Drugs FDA Approval Production Marketing

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

The Pharma Data

JANUARY 31, 2021

In its Phase 1 clinical trial, Clover’s protein-based COVID-19 S-Trimer vaccine candidates in combination with adjuvants from either Dynavax or GlaxoSmithKline plc (GSK, London Stock Exchange: GSK) both performed well and induced high levels of neutralizing antibodies while demonstrating favorable safety and tolerability profiles.

Vaccination

Vaccination Vaccine Trials Protein

Leading innovators in peptide nano-particle conjugates for the pharmaceutical industry

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Antibody

Antibody DNA Development Vaccination

CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision

pharmaphorum

JULY 25, 2022

” GSK’s antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) was the first BCMA-targeting drug to reach the market in 2020, and has since been joined by Carvykti as well as Bristol-Myers Squibb and bluebird bio rival CAR-T therapy Abecma (idecabtagene vicleucel). .”

Antibody

Antibody Medicine Drugs Trials

No sign of stopping: The rise of cell and gene therapy

Drug Discovery World

MAY 22, 2023

Large pharma involvement in advanced therapies has seen ebbs and flows, with AstraZeneca taking a larger stake in the market and Takeda developing its automation and digital capabilities, but also with GSK letting go of its CGT projects, along with most of the staff involved in its R&D. But are these price tags a barrier to access?

Gene Therapy

Gene Therapy Gene Drugs Contamination

A history of Pfizer

pharmaphorum

DECEMBER 2, 2020

In 2017/2018 Pfizer attempted to sell its consumer health unit, but buyers including Proctor & Gamble and GSK pulled out of negotiations. Pfizer and GSK plan to divest the business completely in the long term and reap the rewards, while merging the two businesses is also expected to create cost savings for both partners.

Sales

Sales Production Drugs Marketing

Pharma By The Numbers: A Retrospective Look at the Industry and 20 Years of Xtalks History

XTalks

MARCH 22, 2023

In turn, GSK regained full control of its joint consumer health business with Novartis in 2018. In addition, nearly half of all new drugs launched between 2020 and 2021 came with a price tag of $150,000 per year, or more. However, Alcon has since separated from Novartis in 2019 and is now operating as a standalone eye care company.

Life Science

Life Science Drugs FDA Approval Vaccination

Owkin taps Linux Foundation to open-source its AI learning software

pharmaphorum

NOVEMBER 28, 2022

Substra is the software that powered the MELLODDY platform, a collaboration in which Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck, Novartis, and Servier all agreed to share drug discovery data — but not with each other directly, nor with Owkin.

Pharma Companies

Pharma Companies Life Science Research Development

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

NOVEMBER 13, 2023

Fabian Mohr, PhD, Vice President Research & Development, IBA Lifesciences, on: ‘Developing a robust affinity tag platform using engineered streptavidin’. Opher Gileadi, PhD, Head, Protein Science SGC, Karolinska Institute, on: ‘Targeting every human protein: Challenges and prospects’.

Protein

Protein Antibody Engineer Scientist

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

NOVEMBER 9, 2023

Iain Moal, PhD, Scientific Leader, Computational Antibody Engineering, GSK, on: ‘Learning antibody binding affinity using FACS and NGS’. James Cooke, PhD, Associate Director, Bicycle Therapeutics, on: ‘Engineering bicyclic peptides for precision targeted medicine’.

Engineer

Engineer Antibody Protein In-Vivo

Clinical Research Informer

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet

Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates

Trending Sources

J&J gets first approval for multiple myeloma bispecific Tecvayli

Axsome bounces back as FDA clears depression drug

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

Leading innovators in peptide nano-particle conjugates for the pharmaceutical industry

CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision

No sign of stopping: The rise of cell and gene therapy

A history of Pfizer

Pharma By The Numbers: A Retrospective Look at the Industry and 20 Years of Xtalks History

Owkin taps Linux Foundation to open-source its AI learning software

What to expect from PEGS Europe 2023: Day 3

What to expect from PEGS Europe 2023: Day 2

Stay Connected